Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer
Bristol-Myers Squibb (BMS)
The purpose of this study is to determine which combination of Nivolumab plus either Rucaparib, Docetaxel, or Enzalutamide is the most effective in treating metatstatic, Castration-resistant Prostate Cancer. This is a non-randomized study and participants will be allocated into Arm A (Rucaparib), Arm B (Docetaxel) or Arm C (Enzalutamide), receiving specified doses on specified days.